VITG Competitors

We are accelerating the world's transformation to sustainable materials, by replacing fossil fuel sources with plants. We believe that all products should be responsibly sourced, traceable, and transparent — the sustainable source™. At Geno, we are breaking the planet's reliance on these fossil fuels by creating something better. Our vision to drive climate action at scale starts by making the same molecules, ingredients, and materials we rely on every day, but deriving them from more sustainable sources. Spanning products across a wide variety of industries, Geno’s technologies power high-performance at leading scale and volume, delivering plant-derived ingredients to some of the world’s largest brands. And with that we are shaping the creation of more transparent, traceable, and responsible global supply chains for brands and their consumers to rely on. Our technology and capabilities, developed and honed over two decades, harness the ever-increasing power of biotechnology, where microorganisms and industrial processes are designed to ferment plant sugars into materials and ingredients. Geno's Innovation Center is home to our world-class research and development team of engineers and scientists who have deployed more than $300 million in technology investment, collaborating to create a portfolio of 2,200 patents and applications. The IP covers product pathways, synthetic biology approaches to engineering microorganisms, processes to bio-manufacture products, their sometimes unique biological compositions, and product applications. We work closely with some of the world’s leading brands to develop solutions that align superior performance and economics with sustainability. We also produce and market our own branded products and license our geno technology to some of the world’s largest manufacturers including Novamont, Qore® (a joint venture of Cargill and HELM), Covestro, and Aquafil. Feeling like you’d be a fit? Join us: http://www.genomatica.com/careers/

Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.

Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com